Raf Poppe

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Grazia Arpino, Juan de la Haba-Rodríguez, Jean-­Marc Ferrero et al. · Clinical Cancer Research · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

Ann Gils, Niels Vande Casteele, Raf Poppe et al. · Therapeutic Drug Monitoring · 2014 · 42 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Abstract PD3-02: Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer

Grazia Arpino, Juan de la Haba-Rodríguez, Jean-­Marc Ferrero et al. · Cancer Research · 2021 · 27 citations

Medicine, Oncology, Pharmacology +17

329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer

Sherene Loi, Eun‐Kee Song, Mark Harries et al. · Annals of Oncology · 2021 · 17 citations

Medicine, Oncology, Pharmacology +17

Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients

Sarah Sammons, Thibaut Sanglier, José Pablo Leone et al. · JNCI Journal of the National Cancer Institute · 2025 · 11 citations · Full text

Medicine, Oncology, Breast Oncology +16